Association of serum lipids and severity of epithelial ovarian cancer: an observational cohort study of 349 Chinese patients

Abstract

While obesity and fat intake have been associated with the risk and prognosis of epithelial ovarian cancer, the association between the lipid levels and epithelial ovarian cancer phenotype remains controversial. We conducted a retrospective study of 349 epithelial ovarian cancer patients who received treatment at Jiangsu Cancer Hospital, China between 2011 and 2017. We analyzed age at diagnosis, blood pressure, plasma glucose content, body mass index (BMI), lipid levels and clinical parameters. Severity of epithelial ovarian cancer was classified according to the International Federation of Gynecology and Obstetrics (FIGO) grading system. Univariate analysis of the clinical factors according to the severity of epithelial ovarian cancer was followed by logistic regression analysis to identify clinical factors significantly associated with epithelial ovarian cancer severity. Univariate analysis indicated that age, BMI, triglyceride (TG), and high density lipoproteins (HDL) differed significantly among different stages of epithelial ovarian cancer (P<0.05). In the logistic regression model, elevated TG (OR: 1.883; 95% CI= 1.207–2.937), and low HDL (OR: 0.497; 95% CI= 0.298–0.829) levels were significantly associated with the high severity epithelial ovarian cancer. Our data indicate that high TG and low HDL levels correlate with a high severity of epithelial ovarian cancer. These data provide important insight into the potential relationship between the lipid pathway and epithelial ovarian cancer phenotype and development.

Keywords

triglycerides / epithelial ovarian cancer / high density lipoproteins / dyslipidemia / clinical data statistics

References

[1] Guo H, Zhong Y, Jackson AL, Everolimus exhibits anti-tumorigenic activity in obesity-induced ovarian cancer[J]. Oncotarget, 2016, 7(15): 20338–20356.

[2] Liu H, Liu J, Wang S, Enterolactone has stronger effects than enterodiol on ovarian cancer[J]. J Ovarian Res, 2017, 10(1): 49.

[3] Liu Z, Zhang TT, Zhao JJ, The association between overweight, obesity and ovarian cancer: a meta-analysis[J]. Jpn J Clin Oncol, 2015, 45(12): 1107–1115.

[4] Jia P, Zhang Y. Ovarian preservation improves overall survival in young patients with early-stage endometrial cancer[J]. Oncotarget, 2017, 8(35): 59940–59949.

[5] Xie H, Hou Y, Cheng J, Metabolic profiling and novel plasma biomarkers for predicting survival in epithelial ovarian cancer[J]. Oncotarget, 2017, 8(19): 32134–32146.

[6] Chen Y, Zhang L, Liu W, Case-control study of metabolic syndrome and ovarian cancer in Chinese population[J]. Nutr Metab (Lond), 2017, 14: 21

[7] Nagle CM, Dixon SC, Jensen A, Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium[J]. Br J Cancer, 2015, 113(5): 817–826.

[8] Beavis AL, Smith AJ, Fader AN. Lifestyle changes and the risk of developing endometrial and ovarian cancers: opportunities for prevention and management[J]. Int J Womens Health, 2016, 8: 151–167.

[9] Erondu CO, Alberg AJ, Bandera EV, The association between body mass index and presenting symptoms in African American women with ovarian cancer[J]. J Womens Health (Larchmt), 2016, 25(6): 571–578.

[10] Lees B, Leath CA 3rd. The impact of diabetes on gynecologic cancer: current status and future directions[J]. Curr Obstet Gynecol Rep, 2015, 4(4): 234–239.

[11] Bernardo BM, Orellana RC, Weisband YL, Association between prediagnostic glucose, triglycerides, cholesterol and meningioma, and reverse causality[J]. Br J Cancer, 2016, 115(1): 108–114.

[12] Ghahremanfard F, Mirmohammadkhani M, Shahnazari B, The valuable role of measuring serum lipid profile in cancer progression[J]. Oman Med J, 2015, 30(5): 353–357.

[13] Li AJ, Elmore RG, Chen IY, Serum low-density lipoprotein levels correlate with survival in advanced stage epithelial ovarian cancers[J]. Gynecol Oncol, 2010, 116(1): 78–81.

[14] Li J, Xie H, Li A, Distinct plasma lipids profiles of recurrent ovarian cancer by liquid chromatography-mass spectrometry[J]. Oncotarget, 2017, 8(29): 46834–46845.

[15] Sung HK, Ma SH, Choi JY, The effect of breastfeeding duration and parity on the risk of epithelial ovarian cancer: a systematic review and meta-analysis[J]. J Prev Med Public Health, 2016, 49(6): 349–366.

[16] Liu L, Segura A, Hagemann AR. Obesity education strategies for cancer prevention in women’s health[J]. Curr Obstet Gynecol Rep, 2015, 4(4): 249–258.

[17] Hu Q, Wang M, Cho MS, Lipid profile of platelets and platelet-derived microparticles in ovarian cancer[J]. BBA Clin, 2016, 6: 76–81.

[18] Yao CQ, Nguyen F, Haider S, The transcriptomic profile of ovarian cancer grading[J]. Cancer Med, 2015, 4(1): 56–64.

[19] Bruno E, Manoukian S, Venturelli E, Adherence to mediterranean diet and metabolic syndrome in BRCA mutation carriers[J]. Integr Cancer Ther, 2018, 17(1):153–160.

[20] Bandera EV, Lee VS, Qin B, Impact of body mass index on ovarian cancer survival varies by stage[J]. Br J Cancer, 2017, 117(2): 282–289.

[21] Wang H, Feng Z, Wu D, Enzyme-regulated supramolecular assemblies of cholesterol conjugates against drug-resistant ovarian cancer cells[J]. J Am Chem Soc, 2016, 138(34): 10758–10761.

[22] Mehdizadeh A, Bonyadi M, Darabi M, Common chemotherapeutic agents modulate fatty acid distribution in human hepatocellular carcinoma and colorectal cancer cells[J]. Bioimpacts, 2017, 7(1): 31–39.

[23] Yvan-Charvet L, Wang N, Tall AR. Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses[J]. Arterioscler Thromb Vasc Biol, 2010, 30(2): 139–143.

[24] Esteve E, Ricart W, Fernández-Real JM. Dyslipidemia and inflammation: an evolutionary conserved mechanism[J]. Clin Nutr, 2005, 24(1): 16–31.

[25] Patel VK, Williams H, Li SCH, Monocyte inflammatory profile is specific for individuals and associated with altered blood lipid levels[J]. Atherosclerosis, 2017, 263: 15–23.

[26] Jiang SS, Weng DS, Jiang L, The clinical significance of preoperative serum cholesterol and high-density lipoprotein-cholesterol levels in hepatocellular carcinoma[J]. J Cancer, 2016, 7(6): 626–632.

[27] Sedger LM, Tull DL, McConville MJ, Lipidomic profiling of adipose tissue reveals an inflammatory signature in cancer-related and primary lymphedema[J]. PLoS One, 2016, 11(5): e0154650.

[28] Eroglu M, Yilmaz N, Yalcinkaya S, Enhanced HDL-cholesterol-associated anti-oxidant PON-1 activity in prostate cancer patients[J]. Kaohsiung J Med Sci, 2013, 29(7): 368–373.

[29] Chandler PD, Song Y, Lin J, Lipid biomarkers and long-term risk of cancer in the Women’s Health Study[J]. Am J Clin Nutr, 2016, 103(6): 1397–1407.

[30] Salgado-Montilla J, Soto Salgado M, Surillo Trautmann B, Association of serum lipid levels and prostate cancer severity among Hispanic Puerto Rican men[J]. Lipids Health Dis, 2015, 14: 111.

[31] Ibarguren M, Lopez DJ, Escriba PV. The effect of natural and synthetic fatty acids on membrane structure, microdomain organization, cellular functions and human health[J]. Biochim Biophys Acta, 2014, 1838:1518–1528.

[32] Mustafa G, Kursat FM, Ahmet T, The relationship between erythrocyte membrane fatty acid levels and cardiac autonomic function in obese children[J]. Rev Port Cardiol, 2017, 36(7–8): 499–508.

[33] Capasso I, Esposito E, Pentimalli F, Metabolic syndrome affects breast cancer risk in postmenopausal women: National Cancer Institute of Naples experience[J]. Cancer Biol Ther, 2010, 10(12): 1240–1243.

[34] Alegre MM, Knowles MH, Robison RA, Mechanics behind breast cancer prevention- focus on obesity, exercise and dietary fat[J]. Asian Pac J Cancer Prev, 2013, 14(4): 2207–2212.

[35] Suri A, Sheng X, Schuler KM, The effect of celecoxib on tumor growth in ovarian cancer cells and a genetically engineered mouse model of serous ovarian cancer[J]. Oncotarget, 2016, 7(26): 39582–39594.

[36] Sekine Y, Koike H, Nakano T, Remnant lipoproteins stimulate proliferation and activate MAPK and Akt signaling pathways via G protein-coupled receptor in PC-3 prostate cancer cells[J]. Clin Chim Acta, 2007, 383(1–2): 78–84.

[37] Park J, Morley TS, Kim M, Obesity and cancer--mechanisms underlying tumour progression and recurrence[J]. Nat Rev Endocrinol, 2014, 10(8): 455–465.

Acknowledgments

This study was supported by Jiangsu Cancer Hospital (ZK201606; ZK201610).

RIGHTS & PERMISSIONS

2018 2018 by the Journal of Biomedical Research.